Melina Sophie Kurte

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 6

Top Topics

Molecularly Imprinted

Diffuse Large B Cell Lymphoma

Clinical Evaluation

Top Venues

Cost effectiveness and resource allocation : C/E

European journal of haematology

This page only lists publications with an associated author ORCID identifier.

Publications

Melina Sophie Kurte, Ann-Cathrine Siefen, Florian Jakobs, Tabea Poos, Julia von Tresckow, Bastian von Tresckow, Hans Christian Reinhardt, Florian Kron
Time-dependent cost comparison and health economic impact analysis of second-line interventions for transplant-ineligible patients with relapsed or refractory diffuse large B cell lymphoma. European journal of haematology 113 (3) (2024)
Amelie Wickmann, Melina Sophie Kurte, Julia Jeck, Luisa Camacho, Dennis Klinkhammer, Florian Kron, Robert Dengler
Cost-benefit evaluation of advanced therapy lines in metastatic triple-negative breast cancer in Germany. Cost effectiveness and resource allocation : C/E 22 (1) (2024)
Amelie Wickmann, Melina Sophie Kurte, Julia Jeck, Luisa Camacho, Dennis Klinkhammer, Florian Kron, Robert Dengler
Cost-benefit evaluation of advanced therapy lines in metastatic triple-negative breast cancer in Germany. Cost effectiveness and resource allocation : C/E 22 (1) (2024)
Amelie Wickmann, Melina Sophie Kurte, Julia Jeck, Luisa Camacho, Dennis Klinkhammer, Florian Kron, Robert Dengler
Cost-benefit evaluation of advanced therapy lines in metastatic triple-negative breast cancer in Germany. Cost effectiveness and resource allocation : C/E 22 (1) (2024)
Melina Sophie Kurte, Ann-Cathrine Siefen, Florian Jakobs, Tabea Poos, Julia von Tresckow, Bastian von Tresckow, Hans Christian Reinhardt, Florian Kron
Time-dependent cost comparison and health economic impact analysis of second-line interventions for transplant-ineligible patients with relapsed or refractory diffuse large B cell lymphoma. European journal of haematology (2024)
Amelie Wickmann, Melina Sophie Kurte, Julia Jeck, Luisa Camacho, Dennis Klinkhammer, Florian Kron, Robert Dengler
Cost-benefit evaluation of advanced therapy lines in metastatic triple-negative breast cancer in Germany. Cost effectiveness and resource allocation : C/E 22 (1) (2024)